Open Access
Review
Numéro
Cah. Myol.
Numéro 19, Juin 2019
Page(s) 25 - 27
Section Mise au point / Focus
DOI https://doi.org/10.1051/myolog/201919007
Publié en ligne 5 juillet 2019
  1. Hayes TG, Pharmacologic treatment of male breast cancer. Expert Opin Pharmacother. 2009 ; 10 : 2499–510. [CrossRef] [PubMed] [Google Scholar]
  2. Peddi PF, Hormone receptor positive breast cancer: state of the art. Curr Opin Obstet Gynecol. 2018 ; 30 : 51–4. [PubMed] [Google Scholar]
  3. Chua ME, Escusa KG, Luna S, Tapia LC, Dofitas B, Morales M, Revisiting oestrogen antagonists (clomiphene or tamoxifen) as medical empiric therapy for idiopathic male infertility: a meta-analysis. Andrology. 2013 ; 1 : 749–57. [CrossRef] [PubMed] [Google Scholar]
  4. Payne WG, Ko F, Anspaugh S, Wheeler CK, Wright TE, Robson MC, Down-regulating causes of fibrosis with tamoxifen: a possible cellular/molecular approach to treat rhinophyma. Ann Plast Surg. 2006 ; 56 : 301–5. [CrossRef] [PubMed] [Google Scholar]
  5. Kreher NC, Eugster EA, Shankar RR, The use of tamoxifen to improve height potential in short pubertal boys. Pediatrics. 2005 ; 116 : 1513–5. [CrossRef] [PubMed] [Google Scholar]
  6. Derman O, Kanbur N, Kilic I, Kutluk T, Long-term follow-up of tamoxifen treatment in adolescents with gynecomastia. J Pediatr Endocrinol Metab. 2008 ; 21 : 449–54. [CrossRef] [PubMed] [Google Scholar]
  7. Dorchies OM, Reutenauer-Patte J, Dahmane E, et al. The anticancer drug tamoxifen counteracts the pathology in a mouse model of duchenne muscular dystrophy. Am J Pathol. 2013 ; 182 : 485–504. [CrossRef] [PubMed] [Google Scholar]
  8. Gayi E, Neff LA, Ismail HM, Ruegg UT, Scapozza L, Dorchies OM, Repurposing the selective oestrogen receptor modulator tamoxifen for the treatment of Duchenne muscular dystrophy. Chimia (Aarau). 2018 ; 72 : 238–40. [CrossRef] [PubMed] [Google Scholar]
  9. Cowling BS, Chevremont T, Prokic I, et al. Reducing dynamin 2 expression rescues X-linked centronuclear myopathy. J Clin Invest. 2014 ; 124 : 1350–63. [CrossRef] [PubMed] [Google Scholar]
  10. Gayi E, Neff LA, Massana Muñoz X, et al. Tamoxifen prolongs survival and alleviates symptoms in mice with fatal X-linked myotubular myopathy. Nat Commun. 2018 ; 9 : 4848. [CrossRef] [PubMed] [Google Scholar]
  11. Cowling BS, Prokic I, Tasfaout H, et al. Amphiphysin (BIN1) negatively regulates dynamin 2 for normal muscle maturation. J Clin Invest. 2017 ; 127 : 4477–87. [CrossRef] [PubMed] [Google Scholar]
  12. Demonbreun AR, McNally EM, Dynamin 2 the rescue for centronuclear myopathy. J Clin Invest. 2014 ; 124 : 976–8. [CrossRef] [PubMed] [Google Scholar]
  13. Böhm J, Vasli N, Maurer M, et al., Altered splicing of the BIN1 muscle-specific exon in humans and dogs with highly progressive centronuclear myopathy. PLoS Genet. 2013 ; 9 : e1003430. [Google Scholar]
  14. Ismail HM, Dorchies OM, Scapozza L, The potential and benefits of repurposing existing drugs to treat rare muscular dystrophies. Expert Opin Orphan Drugs. 2018 ; 6 : 259–71. [Google Scholar]

Les statistiques affichées correspondent au cumul d'une part des vues des résumés de l'article et d'autre part des vues et téléchargements de l'article plein-texte (PDF, Full-HTML, ePub... selon les formats disponibles) sur la platefome Vision4Press.

Les statistiques sont disponibles avec un délai de 48 à 96 heures et sont mises à jour quotidiennement en semaine.

Le chargement des statistiques peut être long.